Cavanna Andrea E, Capriolo Elisa, Caimi Virginia, Arienti Gabriele, Riva Anna, Nacinovich Renata, Seri Stefano
Department of Neuropsychiatry, BSMHFT and School of Medical Sciences, College of Medicine and Health, University of Birmingham, Birmingham, UK.
Sobell Department of Motor Neuroscience and Movement Disorders, Institute of Neurology, University College London, London, UK.
Neurol Sci. 2025 Sep 16. doi: 10.1007/s10072-025-08496-x.
Myopia has been reported as a rare adverse effect of aripiprazole, a third-generation antidopaminergic medication used for the treatment of different neuropsychiatric conditions, including psychotic disorders, affective disorders, and obsessive-compulsive disorder.
We document the rare case of a 29-year-old woman diagnosed with a neurodevelopmental tic disorder (Tourette syndrome) who developed bilateral myopia while taking aripiprazole 15 mg daily as a first-line anti-tic agent. Her myopia completely regressed following a decrease in the dose of aripiprazole from 15 mg to 10 mg daily.
To date, a total of 11 cases presenting with aripiprazole-induced reversible myopia (9 females, age range 19-34 years) have been reported. In addition to broadening the spectrum of the treated conditions, our case report raises the possibility of dose-dependent mechanisms underlying the development of myopia, at least in selected cases.
阿立哌唑是一种用于治疗不同神经精神疾病（包括精神障碍、情感障碍和强迫症）的第三代抗多巴胺能药物，近视已被报道为其一种罕见的不良反应。
我们记录了一例罕见病例，一名29岁被诊断为神经发育性抽动障碍（图雷特综合征）的女性，在每日服用15毫克阿立哌唑作为一线抗抽动药物时出现了双侧近视。在将阿立哌唑剂量从每日15毫克减至10毫克后，她的近视完全消退。
迄今为止，共报告了11例阿立哌唑引起的可逆性近视病例（9名女性，年龄范围19 - 34岁）。除了拓宽治疗疾病的范围外，我们的病例报告还提出了至少在某些特定病例中，近视发展存在剂量依赖性机制的可能性。
